Abstract Background: The stage of fibrosis is a sensitive predictor of sustained virological response to Pegylated INF/Ribavirin in chronic hepatitis C. Aim of Study: To assess the value of liver fibrosis as a predictor of SVR. Patients and Methods: This study was a retrospective controlled study and was performed on a total number of 240 patients who were treated by PEG-IFN alpha/RBV for 48 weeks and fibrosis stage was done for the all patients. Results: SVR was significant high in patients with F0 and F1 fibrosis stage. Conclusion: The fibrosis stage was a strong pretreatment predictor of response to pegylated interferon and ribavirin therapy in egyptian patients chronically infected with HCV genotype 4.